Overview

Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine after surgery, radiation therapy, and/or chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone previous surgery, radiation therapy, and/or chemotherapy for head and neck cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Barbara Ann Karmanos Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Capecitabine